{"id":348,"date":"2013-12-12T09:18:04","date_gmt":"2013-12-12T09:18:04","guid":{"rendered":"https:\/\/sagaciousresearch.com\/blog\/?p=348"},"modified":"2022-09-26T06:10:30","modified_gmt":"2022-09-26T06:10:30","slug":"tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","status":"publish","type":"post","link":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","title":{"rendered":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents"},"content":{"rendered":"\n

Some tips to overcome U.S. Obviousness Rejections For Bio-Pharma Patents-<\/p>\n\n\n\n

\u2022 Don\u2019t always argue the existence of an examiner-asserted presumption of prima facie obviousness (PFO)<\/p>\n\n\n\n

\u2022 Use a selection argument, also map out each step needed to arrive at the claimed invention.<\/p>\n\n\n\n

Our Services:<\/strong>
Patent Drafting Support<\/a> | Fixed and Cost-effective Patent Searches | Patent Searches<\/a> | Prior Art Search<\/a> | Bio-Sequence Patents<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Some tips to overcome U.S. Obviousness Rejections For Bio-Pharma Patents- \u2022 Don\u2019t always argue the existence of an examiner-asserted presumption of prima facie obviousness (PFO) \u2022 Use a selection argument, also map out each...<\/p>\n","protected":false},"author":1,"featured_media":25867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"coauthors":[983],"class_list":["post-348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles"],"acf":[],"yoast_head":"\nTips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP\" \/>\n<meta property=\"og:description\" content=\"Some tips to overcome U.S. Obviousness Rejections For Bio-Pharma Patents- \u2022 Don\u2019t always argue the existence of an examiner-asserted presumption of prima facie obviousness (PFO) \u2022 Use a selection argument, also map out each...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\" \/>\n<meta property=\"og:site_name\" content=\"Sagacious IP\" \/>\n<meta property=\"article:published_time\" content=\"2013-12-12T09:18:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-26T06:10:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2100\" \/>\n\t<meta property=\"og:image:height\" content=\"1400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vilas Karnake\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vilas Karnake\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#article\",\"isPartOf\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\"},\"author\":{\"name\":\"Vilas Karnake\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f\"},\"headline\":\"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents\",\"datePublished\":\"2013-12-12T09:18:04+00:00\",\"dateModified\":\"2022-09-26T06:10:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\"},\"wordCount\":71,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg\",\"articleSection\":[\"Articles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\",\"name\":\"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP\",\"isPartOf\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage\"},\"thumbnailUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg\",\"datePublished\":\"2013-12-12T09:18:04+00:00\",\"dateModified\":\"2022-09-26T06:10:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg\",\"contentUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg\",\"width\":2100,\"height\":1400,\"caption\":\"Bio-Pharma Patents\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sagaciousresearch.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#website\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/\",\"name\":\"Sagacious IP\",\"description\":\"Blog\",\"publisher\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sagaciousresearch.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#organization\",\"name\":\"Sagacious IP\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png\",\"contentUrl\":\"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png\",\"width\":481,\"height\":80,\"caption\":\"Sagacious IP\"},\"image\":{\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f\",\"name\":\"Vilas Karnake\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/image\/d7edb6a9166e3680603701ae9e10e107\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk\",\"caption\":\"Vilas Karnake\"},\"url\":\"https:\/\/sagaciousresearch.com\/blog\/author\/adm.vkarnake\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","og_locale":"en_US","og_type":"article","og_title":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP","og_description":"Some tips to overcome U.S. Obviousness Rejections For Bio-Pharma Patents- \u2022 Don\u2019t always argue the existence of an examiner-asserted presumption of prima facie obviousness (PFO) \u2022 Use a selection argument, also map out each...","og_url":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","og_site_name":"Sagacious IP","article_published_time":"2013-12-12T09:18:04+00:00","article_modified_time":"2022-09-26T06:10:30+00:00","og_image":[{"width":2100,"height":1400,"url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg","type":"image\/jpeg"}],"author":"Vilas Karnake","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Vilas Karnake","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#article","isPartOf":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents"},"author":{"name":"Vilas Karnake","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f"},"headline":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents","datePublished":"2013-12-12T09:18:04+00:00","dateModified":"2022-09-26T06:10:30+00:00","mainEntityOfPage":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents"},"wordCount":71,"commentCount":0,"publisher":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#organization"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage"},"thumbnailUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg","articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","url":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents","name":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents - Sagacious IP","isPartOf":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage"},"thumbnailUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg","datePublished":"2013-12-12T09:18:04+00:00","dateModified":"2022-09-26T06:10:30+00:00","breadcrumb":{"@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#primaryimage","url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg","contentUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2013\/12\/10-1.jpg","width":2100,"height":1400,"caption":"Bio-Pharma Patents"},{"@type":"BreadcrumbList","@id":"https:\/\/sagaciousresearch.com\/blog\/tips-to-overcome-u-s-obviousness-rejections-for-bio-pharma-patents#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sagaciousresearch.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Tips To Overcome U.S. Obviousness Rejections\u00a0For Bio-Pharma Patents"}]},{"@type":"WebSite","@id":"https:\/\/sagaciousresearch.com\/blog\/#website","url":"https:\/\/sagaciousresearch.com\/blog\/","name":"Sagacious IP","description":"Blog","publisher":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sagaciousresearch.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sagaciousresearch.com\/blog\/#organization","name":"Sagacious IP","url":"https:\/\/sagaciousresearch.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png","contentUrl":"https:\/\/sagaciousresearch.com\/blog\/wp-content\/uploads\/2022\/06\/cropped-cropped-cropped-sagacious-ip-logo80-1-1.png","width":481,"height":80,"caption":"Sagacious IP"},"image":{"@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/ee18415b4ec48919d929dd9732c9749f","name":"Vilas Karnake","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sagaciousresearch.com\/blog\/#\/schema\/person\/image\/d7edb6a9166e3680603701ae9e10e107","url":"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/363be32d5f469b83f76184b09a333c02c746a62144121a8dcfc89b20ff076462?s=96&d=initials&r=g&initials=vk","caption":"Vilas Karnake"},"url":"https:\/\/sagaciousresearch.com\/blog\/author\/adm.vkarnake"}]}},"_links":{"self":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/comments?post=348"}],"version-history":[{"count":4,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/348\/revisions"}],"predecessor-version":[{"id":25868,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/posts\/348\/revisions\/25868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/media\/25867"}],"wp:attachment":[{"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/media?parent=348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/tags?post=348"},{"taxonomy":"categories","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/categories?post=348"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/sagaciousresearch.com\/blog\/wp-json\/wp\/v2\/coauthors?post=348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}